

Regenerative Medicine and Neurodegenerative Disorders: Regulatory Considerations

CIRM Brainstorming Neurodegeneration

April 15, 2019

Wilson W. Bryan, MD







- ... protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; ...
- ... advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable ...



FDA Organization



Center for Biologics Evaluation and Research (CBER)



Office of Vaccines Research and Review Office of Blood Research and Review Office of Tissues and Advanced Therapies

Diversity of OTAT-Regulated Products



Gene therapies (GT)

- Ex vivo genetically modified cells
- Non-viral vectors (e.g., plasmids)
- Replication-deficient viral vectors (e.g., adenovirus, adeno-associated virus, lentivirus)
- Replication-competent viral vectors (e.g., measles, adenovirus, vaccinia)
- Microbial vectors (e.g., Listeria, Salmonella)
- Stem cells/stem cell-derived
 - Adult (e.g., hematopoietic, neural, cardiac, adipose, mesenchymal)
 - Perinatal (e.g., placental, umbilical cord blood)
 - Fetal (e.g., neural)
 - Embryonic
 - Induced pluripotent stem cells (iPSCs)
- Products for xenotransplantation

- Functionally mature/differentiated cells (e.g., retinal pigment epithelial cells, pancreatic islets, chondrocytes, keratinocytes)
- Therapeutic vaccines and cellular immunotherapies including antigen-specific active immunotherapies
- Blood- and Plasma-derived products
 - Coagulation factors
 - Fibrin sealants
 - Fibrinogen
 - Thrombin
 - Plasminogen
 - Immune globulins
 - Anti-toxins
 - Snake venom antisera
- Combination products
 - Engineered tissues/organs
- Devices
- Tissues

Applications to FDA




- Clinical Development (Clinical Trials)
 - IND: Investigational New Drug Application

For drugs and biologics

- IDE: Investigational Device Exemption Application
- Marketing
 - BLA: Biologics License Application
 - NDA: New Drug Application
 - Devices:
 - Premarket Approval (PMA) or 510k Application




IND Submissions with Gene Therapy Products, CY 1963 – 2018






IND Submissions with Cell Therapy Products, CY 1963 – 2018



IND Submissions for Neurology FDA Indications, 2002-2018






- During development (IND): Designations
 - Fast Track
 - Breakthrough
 - Regenerative Medicine Advanced Therapy
- Marketing Application (NDA or BLA)
 - Priority Review
 - Accelerated Approval



21st Century Cures Act December 13, 2016





21st Century Cures Act Section 3033: Definition of Regenerative Medicine Therapy (RMT)

Includes cell therapy, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the Public Health Service Act ...



Definition of Regenerative Medicine Therapy (RMT)

- Guidance for Industry: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
- Interprets RMT definition to also include:
 - Gene therapies that lead to a sustained effect on cells or tissues
 - Certain xenogeneic cell therapies




Section 3033: Regenerative Medicine Advanced Therapy (RMAT) Designation

- Creates program for designation of regenerative medicine advanced therapies
- A drug is eligible for designation if:
 - It is a regenerative medicine therapy
 - The drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and
 - Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition




Benefits of RMAT Designation

- Interactions with FDA to expedite development and review of regenerative medicine advanced therapies
 - Benefits available to breakthrough therapies
 - Including early discussions of any potential surrogate or intermediate endpoints to support accelerated approval




Granted RMAT Designation Requests Specialtie - as of April 13, 2019



Granted RMAT Designation Requests - Distribution by Product Type





Cell Therapy Product
Autologous Cells

Cell Therapy Product
Allogeneic Cells

Gene Therapy


Combination and Tissue Engineering

Analysis of Denied RMAT Designation Requests



- Administrative Reasons
 - Inactive IND
 - No preliminary clinical evidence submitted
- CMC Reasons
 - Different product, lack of product comparability data
- Insufficient Preliminary Clinical Evidence
 - Study design issues
 - Inconsistent results with regard to product activity

Cumulative Sum of BTD and RMAT Designation Requested and Granted BTDs and RMAT Designations (through April 13, 2019)



www.fda.gov

INitial Targeted Engagement for Regulatory Advice on CBER producTs (previously known as pre-pre-IND interactions)



FDA

Applications to FDA



- Clinical Development (Clinical Trials)
 - IND: Investigational New Drug Application
 - For drugs and biologics
 - IDE: Investigational Device Exemption Application
- Marketing

-BLA: Biologics License Application

- NDA: New Drug Application
- Devices:

Premarket Approval (PMA) or 510k Application

Marketing Approval for Drugs and Biologics



- Requirements
 - Substantial evidence of effectiveness
 - Adequate and well-controlled investigations
 - Safety (sufficient to support an overall favorable benefit-risk assessment)
- Types of approval
 - Traditional (aka: standard; regular)
 - Accelerated



Traditional Approval

 Evidence of effectiveness based on an effect on clinically meaningful endpoint(s) (e.g., how a patient feels, functions, or survives)

 No comparative effectiveness requirement (i.e., must be better than no treatment or placebo, but does not need to be better than currently available therapies)



Accelerated Approval (AA)

- Evidence of effectiveness based on an effect on a surrogate endpoint (or intermediate clinical endpoint) that is reasonably likely to predict a drug's clinical benefit
- Treats a serious or life-threatening condition
- Provides a meaningful advantage over existing treatments

Marketing Approval for Drugs and Biologics



- Requirements
 - Substantial evidence of effectiveness
 - Adequate and well-controlled investigations
 - Safety (sufficient to support an overall favorable benefit-risk assessment)
- Types of approval
 - Traditional (aka: standard; regular)
 - Accelerated


Approved Cell and Gene Therapies

- HPC Cord Blood (multiple banks approved)
- LAVIV (Azficel-T)
- MACI (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane)
- GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen)
- PROVENGE (sipuleucel-T)
- IMLYGIC (talimogene laherparepvec)
- KYMRIAH (tisagenlecleucel)
- YESCARTA (axicabtagene ciloleucel)
- LUXTURNA (voretigene neparvovec-rzyl)

https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/default.htm

CAR T Cells: A Novel Way to Treat Cancer






Shannon L. Maude et al. Blood 2015

CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex



Philadelphia City Hall





www.fda.gov













Current OTAT Vacancies: 43

Cell and Gene Therapy (CMC)	12
Clinical Evaluation and Pharmacology / Toxicology	20
Regulatory Project Management	7
Human Tissues	2
Plasma Protein Therapeutics	0
Immediate Office of Director	2



Acknowledgements

- Rachael Anatol, PhD
- Kim Benton, PhD
- Larissa Lapteva, MD
- Anne Rowzee, PhD
- Keisa Toppin
- Xiaofei Wang, PhD















Contact Information

Wilson W. Bryan, M.D. wilson.bryan@fda.hhs.gov





Contact Information



OTAT Main Line – 240 402 8190 Email: <u>OTATRPMS@fda.hhs.gov</u> and Lori.Tull@fda.hhs.gov

• OTAT Learn Webinar Series:

http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/upm2322821.htm

- **CBER website:** <u>www.fda.gov/BiologicsBloodVaccines/default.htm</u>
- Phone: 1-800-835-4709 or 240-402-8010
- Consumer Affairs Branch: <u>ocod@fda.hhs.gov</u>
- Manufacturers Assistance and Technical Training Branch: industry.biologics@fda.hhs.gov
- Follow us on Twitter: <u>https://www.twitter.com/fdacber</u>









Regenerative Medicine and Neurodegenerative Disorders: Regulatory Considerations

CIRM Brainstorming Neurodegeneration

April 15, 2019

Wilson W. Bryan, MD